drugset / Trial / NCT06965309
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
Terminated
9 enrolled
Shenzhen MagicRNA Biotechnology Co., Ltd
Shanghai General Hospital (Songjiang Branch) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in refractory myasthenia gravis
Timeline
- Start
- 2026-01-19
- Primary completion
- 2026-02-11
- Completion
- 2026-02-11
Outcome
Outcome not reported
Stopped: “Change of registrant”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HN2301 | Cell therapy | — | — |